GSK

growth-positive

Roche has announced its acquisition of 89bio, a clinical-stage biopharmaceutical company, for $3.5 billion. This strategic move aims to enhance Roches portfolio in cardiovascular, renal, and metabolic diseases by adding 89bios promising phase III candidate, pegozafermin, to its pipeline. Pegozafermin is in late-stage development for treating metabolic dysfunction-associated steatohepatitis (MASH) in fibrotic and cirrhotic patients. The acquisition, approved by both companies boards, is expected to close in the fourth quarter of 2025. The deal includes a contingent value right (CVR) for 89bio stockholders, potentially increasing the total consideration by up to $1 billion if certain sales milestones are met. This acquisition is seen as a positive growth opportunity for Roche, aligning with its strategic focus on lucrative therapeutic areas.

growth-positive

The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.

growth-positive

Nutritional Growth Solutions (NG Solutions) has signed a license agreement with GlaxoSmithKline Consumer Healthcare Pte Ltd (GSK). GSK will produce and market Horlicks Growth+, a formula developed by the Schneider Childrens Medical Center of Israel to enhance height and weight in pre pubertal children. The product was launched in India in May 2016 under the Horlicks brand. The product is targeted towards 3-9 year old children who are short or lean for their age. The agreement is seen as a major milestone for NG Solutions.

growth-positive

The UK Israel Tech Hub at the British Embassy Israel is hosting a delegation of industry scientists from the British pharmaceutical firm GlaxoSmithKline (GSK). The purpose of this visit is to facilitate cooperation between Israeli academic scientists and GSK. This is the first time such a team from GSK has visited Israel. The GSK industry experts lead an initiative called “Discovery Partnerships with Academia”, which is aimed at finding new medicines using a unique model for cooperation.